Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

W011 - Hands-on: Varicose and Telangiectatic Veins

Monday, February 19; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Describe the anatomy of the lower extremity venous system and identify patient characteristics that warrant noninvasive imaging prior to initiating treatment.
  • Formulate an appropriate treatment plan for leg veins ranging from spider veins to truncal varicosities.
  • Determine the appropriate use of sclerotherapy, lasers, and more advanced venous techniques and recite the advantages and disadvantages of each treatment modality.

Description

This hands-on training session will focus on how to manage lower extremity venous disease, with an emphasis on treating cosmetically undesirably spider and reticular veins of the legs. Faculty will describe the anatomy of the lower extremity venous system; identify patient characteristics that warrant noninvasive imaging; formulate an appropriate treatment plan for leg veins ranging from spider veins to truncal varicosities; determine the appropriate use of sclerotherapy, lasers, and more advanced venous techniques; and recite the advantages and disadvantages of each treatment modality. Following the didactic portion, participants will break into small groups and circulate through hands-on stations staffed by instructors, where they will practice patient examination with ultrasound and perform sclerotherapy on multiple simulation training devices. This activity has been approved by the American Board of Dermatology (ABD) for up to 30 MOC Component 2 Self-Assessment points. For more information about MOC, please visit the ABD website at www.abderm.org.

Disclosures

  • Friedmann, Daniel Pablo, MD: Aclaris Therapeutics Inc. – SP(H); Aclaris Therapeutics, Inc. – A(H); Allergan, Inc. – C(H), I(Fees), Speaker/Faculty Education(H); Galderma Laboratories, LP – I(Fees); Lumenis – I(EQ), I(Grants/Research Funding); Merz Aesthetics – C(H), I(Fees), Speaker/Faculty Education(H); Suneva Medical, Inc. – SP(H); Zeltiq Aesthetics – I(Grants/Research Funding);
  • Goldman, Mitchel Paul, MD: Allergan, Inc. – A(Grants/Research Funding), I(Grants/Research Funding); DUSA Pharmaceuticals, Inc – I(Grants/Research Funding); Galderma USA – C(H), I(Grants/Research Funding); Lumenis – C(Fees), I(EQ); Merz Aesthetics – C(Grants/Research Funding), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(Fees), I(Grants/Research Funding); SkinMedica, Inc. – C(H); SkinMedica, Inc. – I(Grants/Research Funding); Solta Medical – I(Grants/Research Funding); Syneron, Inc. – I(EQ); Valeant Pharmaceuticals International – C(H);
  • Graves, Michael S, MD: no financial relationships exist with commercial interests.
  • Karen, Julie K., MD: Allergan, Inc – C(Fees); Energizer Holdings, Inc – C(Fees);
  • Mann, Margaret W., MD: Galderma USA – I(Grants/Research Funding); Sciton Inc. – I(EQ);
  • Mishra, Vineet, MD: Cutera, Inc. – I(EQ); Strata Skin Sciences – I(EQ); Theravant Corporation – I(EQ);
  • Munavalli, Girish S., MD, MHS: BTG PLC – A(H); Covidien – C(H); Fibrocell Sciences – A(H); Lumenis – I(EQ); Merz Aesthetics – A(H);
  • Weiss, Margaret A., MD: Allergan, Inc – A(H), C(H), I(Grants/Research Funding); BTG PLC – C(Fees), I(Grants/Research Funding); Cabochon – I(EQ); Canfield Scientific, Inc. – C(H); Cooltouch – C(EQ), C(H); Cynosure – A(H), SP(H); Cynosure, Inc – I(Grants/Research Funding); Evolus, Inc. – I(Grants/Research Funding); Fibrocell Sciences – A(H); Galderma USA – A(H), C(Fees), I(Grants/Research Funding); L'Oreal USA Inc. – C(Fees); Merz Aesthetics – C(H), Data Safety Monitoring Board(Fees), I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sapheon, Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); Suneva Medical, Inc. – A(H); Syneron, Inc. – I(Grants/Research Funding);
  • Weiss, Robert A., MD: Allergan, Inc – A(H), C(Fees), C(H); Allergan, Inc. – I(Grants/Research Funding); Brickell Biotech, Inc. – I(Grants/Research Funding); BTL Industries – I(Grants/Research Funding); Cutanea Life Sciences – I(Grants/Research Funding); Cutera, Inc. – Speaker/Faculty Education(Fees); Cynosure, Inc – A(Fees), I(Grants/Research Funding); Cynosure, Inc. – SP(Fees); Evolus, Inc. – I(Grants/Research Funding); Fibrocell Sciences – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); Galderma USA – SP(H); Lutronic – I(Grants/Research Funding); Lutronics, Inc. – SP(H); Merz Aesthetics – A(H), I(Grants/Research Funding), SP(Fees); Merz Pharmaceuticals, LLC – C(H); Revance Therapeutics, Inc. – I(Grants/Research Funding); Sapheon, Inc. – I(Grants/Research Funding); Sebacia, Inc. – I(Grants/Research Funding); SkinCeauticals LLC – A(Fees); Syneron Candela – A(IP), I(Grants/Research Funding), SP(Fees); ThermiAesthetics – SP(H); Valeant Pharmaceuticals International – I(Grants/Research Funding); Zeltiq Aesthetics – I(Grants/Research Funding);
  • Wysong, Ashley, MD, MS: Castle Biosciences – I(Grants/Research Funding);
Event Details
  • Date
    Monday, February 19
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 11B
  • CME Credits
    3.00
  • Type
    Ticketed
    MOC
    Restricted
Directors/Co-Directors
  • Margaret W. Mann, MD, FAAD
  • Ashley Wysong, MD, MS, FAAD
Speakers
  • Daniel Pablo Friedmann, MD, FAAD
  • Girish S. Munavalli, MD, MHS, FAAD
  • Julie K. Karen, MD, FAAD
  • Margaret A. Weiss, MD, FAAD
  • Michael S Graves, MD, FAAD
  • Mitchel Paul Goldman, MD, FAAD
  • Robert A. Weiss, MD, FAAD
  • Vineet Mishra, MD, FAAD